Inhibition by norharman of metabolism of benzo[a]pyrene by the microsomal mixed function oxidase of rat liver. 1980

T Fujino, and A Matsuyama, and M Nagao, and T Sugimura

The effect of norharman on the metabolism of ethyl acetate-soluble metabolic intermediates of benzo[a]pyrene (BP), 9,10-dihydro-9,10-dihydroxybenzo[a]pyrene (9,10-diol), 4,5-dihydro-4,5-dihydroxybenzo[a]pyrene (4,5-diol), 7,8-dihydro-7,8-dihydroxybenzo[a]pyrene (7,8-diol), benzo[a]pyrene diones, 3-hydroxybenzo[a]pyrene (3-OH-BP) and 9-hydroxybenzo[a]pyrene (9-OH-BP), were studied. These metabolic intermediates were converted by microsomal enzymes to other more polar ethyl acetate-soluble metabolites and then finally to the water-soluble metabolites. Norharman inhibited markedly the disappearance of each metabolite added as a substrate. With high-pressure liquid chromatographic (HPLC) separation it was revealed that formation of more polar metabolite was more efficiently inhibited by norharman than the formation of less polar metabolite. Formation of water-soluble metabolite was most efficiently inhibited by norharman. The mechanisms of the inhibitory effect of norharman on BP metabolism were studied by difference spectroscopy. On the addition of norharman, microsomes showed a type II difference spectrum, while on the addition of BP, they showed a type I difference spectrum. 3-OH-BP and 4,5-diol also gave a type I spectrum. Thus both BP and its metabolites bind to the active center of P-450, whereas norharman binds to the sixth ligand position of the iron ion of P-450. Kinetic studies showed that the Km-value of microsomes for BP was 6.25 microM in the presence and absence of norharman. This indicated that norharman inhibits the metabolism of BP non-competitively.

UI MeSH Term Description Entries
D007700 Kinetics The rate dynamics in chemical or physical systems.
D008297 Male Males
D008658 Inactivation, Metabolic Reduction of pharmacologic activity or toxicity of a drug or other foreign substance by a living system, usually by enzymatic action. It includes those metabolic transformations that make the substance more soluble for faster renal excretion. Detoxication, Drug, Metabolic,Drug Detoxication, Metabolic,Metabolic Detoxication, Drug,Detoxification, Drug, Metabolic,Metabolic Detoxification, Drug,Metabolic Drug Inactivation,Detoxication, Drug Metabolic,Detoxication, Metabolic Drug,Detoxification, Drug Metabolic,Drug Inactivation, Metabolic,Drug Metabolic Detoxication,Drug Metabolic Detoxification,Inactivation, Metabolic Drug,Metabolic Drug Detoxication,Metabolic Inactivation
D008862 Microsomes, Liver Closed vesicles of fragmented endoplasmic reticulum created when liver cells or tissue are disrupted by homogenization. They may be smooth or rough. Liver Microsomes,Liver Microsome,Microsome, Liver
D010088 Oxidoreductases The class of all enzymes catalyzing oxidoreduction reactions. The substrate that is oxidized is regarded as a hydrogen donor. The systematic name is based on donor:acceptor oxidoreductase. The recommended name will be dehydrogenase, wherever this is possible; as an alternative, reductase can be used. Oxidase is only used in cases where O2 is the acceptor. (Enzyme Nomenclature, 1992, p9) Dehydrogenases,Oxidases,Oxidoreductase,Reductases,Dehydrogenase,Oxidase,Reductase
D002243 Carbolines A group of pyrido-indole compounds. Included are any points of fusion of pyridine with the five-membered ring of indole and any derivatives of these compounds. These are similar to CARBAZOLES which are benzo-indoles. Carboline,Pyrido(4,3-b)Indole,Beta-Carbolines,Pyrido(4,3-b)Indoles,Beta Carbolines
D006247 Harmine Alkaloid isolated from seeds of PEGANUM HARMALA; ZYGOPHYLLACEAE. It is identical to banisterine, or telepathine, from Banisteria caapi and is one of the active ingredients of hallucinogenic drinks made in the western Amazon region from related plants. It has no therapeutic use, but (as banisterine) was hailed as a cure for postencephalitic PARKINSON DISEASE in the 1920's. 9H-Pyrido(3,4-b)indole, 7-methoxy-1-methyl-,Banisterine,Leucoharmine,Telepathine,Yageine
D006899 Mixed Function Oxygenases Widely distributed enzymes that carry out oxidation-reduction reactions in which one atom of the oxygen molecule is incorporated into the organic substrate; the other oxygen atom is reduced and combined with hydrogen ions to form water. They are also known as monooxygenases or hydroxylases. These reactions require two substrates as reductants for each of the two oxygen atoms. There are different classes of monooxygenases depending on the type of hydrogen-providing cosubstrate (COENZYMES) required in the mixed-function oxidation. Hydroxylase,Hydroxylases,Mixed Function Oxidase,Mixed Function Oxygenase,Monooxygenase,Monooxygenases,Mixed Function Oxidases,Function Oxidase, Mixed,Function Oxygenase, Mixed,Oxidase, Mixed Function,Oxidases, Mixed Function,Oxygenase, Mixed Function,Oxygenases, Mixed Function
D000470 Alkaloids Organic nitrogenous bases. Many alkaloids of medical importance occur in the animal and vegetable kingdoms, and some have been synthesized. (Grant & Hackh's Chemical Dictionary, 5th ed) Alkaloid,Plant Alkaloid,Plant Alkaloids,Alkaloid, Plant,Alkaloids, Plant
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia

Related Publications

T Fujino, and A Matsuyama, and M Nagao, and T Sugimura
February 1980, Carcinogenesis,
T Fujino, and A Matsuyama, and M Nagao, and T Sugimura
November 1981, Archives of biochemistry and biophysics,
T Fujino, and A Matsuyama, and M Nagao, and T Sugimura
March 1994, Comparative biochemistry and physiology. Pharmacology, toxicology and endocrinology,
T Fujino, and A Matsuyama, and M Nagao, and T Sugimura
April 1967, Biochemical pharmacology,
T Fujino, and A Matsuyama, and M Nagao, and T Sugimura
May 1983, Molecular pharmacology,
T Fujino, and A Matsuyama, and M Nagao, and T Sugimura
May 1978, Biochemical and biophysical research communications,
T Fujino, and A Matsuyama, and M Nagao, and T Sugimura
December 1978, Biochemical and biophysical research communications,
T Fujino, and A Matsuyama, and M Nagao, and T Sugimura
October 1979, Cancer research,
T Fujino, and A Matsuyama, and M Nagao, and T Sugimura
April 1981, Biochemical pharmacology,
Copied contents to your clipboard!